Key Insights

Highlights

Success Rate

86% trial completion

Published Results

26 trials with published results (31%)

Research Maturity

61 completed trials (72% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

11.8%

10 terminated out of 85 trials

Success Rate

85.9%

-0.6% vs benchmark

Late-Stage Pipeline

9%

8 trials in Phase 3/4

Results Transparency

43%

26 of 61 completed with results

Key Signals

26 with results86% success

Data Visualizations

Phase Distribution

72Total
Not Applicable (12)
Early P 1 (3)
P 1 (24)
P 2 (25)
P 3 (6)
P 4 (2)

Trial Status

Completed61
Terminated10
Recruiting5
Unknown4
Active Not Recruiting3
Not Yet Recruiting1

Trial Success Rate

85.9%

Benchmark: 86.5%

Based on 61 completed trials

Clinical Trials (85)

Showing 20 of 20 trials
NCT06585449Phase 1RecruitingPrimary

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

NCT06873334Phase 2Active Not Recruiting

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

NCT01860339CompletedPrimary

Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

NCT07246941Phase 1RecruitingPrimary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

NCT02855476RecruitingPrimary

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

NCT07536061Phase 1Not Yet RecruitingPrimary

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

NCT06634628Early Phase 1Recruiting

iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

NCT05655520Phase 3TerminatedPrimary

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

NCT04120493Phase 1Active Not RecruitingPrimary

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

NCT05107128Phase 2CompletedPrimary

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

NCT02252380Not ApplicableActive Not Recruiting

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

NCT03664804Phase 1CompletedPrimary

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

NCT04000594Phase 1CompletedPrimary

A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease

NCT01931644Completed

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT03761849Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

NCT01574053RecruitingPrimary

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

NCT01592552Completed

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

NCT00670709CompletedPrimary

Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

NCT00491842CompletedPrimary

Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD

NCT00665223Phase 3CompletedPrimary

A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

Scroll to load more

Research Network

Activity Timeline